Dentonin® or AC-100 is a novel synthetic peptide derived from an endogenous human protein produced by bone and dental cells that can stimulate the formation of new dentin (the hard tissue of teeth that protects the tooth pulp and supports the outer enamel) when applied directly to tooth defects.
The success of its Phase 2 clinical trial including favorable safety profile has been announced and presented by Acologix, Inc. at the Annual Meeting of the American Association for Dental Research (AADR) in The research team believes that this Phase 2 clinical study demonstrates that a novel biological approach to dentistry, by modulating normal cell functions to stimulate the innate biological defenses of the tooth, can be introduced as a supplement to routine dental care.
Source: Acologix, Inc. News
.jpg)
Comment Preview